Amylyx (NASDAQ: AMLX) director receives 24,372-share stock option grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Amylyx Pharmaceuticals director Daphne Quimi received a stock option grant covering 24,372 shares of Common Stock. The option has an exercise price of $14.31 per share and expires on June 3, 2036. It vests in full on the earlier of June 4, 2027 or the next annual meeting, subject to her continuous service, and represents her entire reported option position in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Quimi Daphne

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	24,372	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 24,372 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 24,372 options Exercise price: $14.31 per share Expiration date: June 3, 2036 +3 more

6 metrics

Option grant size 24,372 options Stock Option (right to buy) granted to director Daphne Quimi

Exercise price $14.31 per share Conversion or exercise price of granted stock options

Expiration date June 3, 2036 Option expiration for 24,372-share grant

Vesting date Earlier of June 4, 2027 or next annual meeting Full vesting subject to continuous service

Total options after grant 24,372 options Total derivative securities following transaction

Transaction price per option $0.00 Grant/award acquisition, no cash paid for options

Key Terms

Stock Option (right to buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 14.3100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"shares subject to this option shall vest in full upon the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/08/2026 - 04:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quimi Daphne

(Last)

(First)

(Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$14.31	06/04/2026		A		24,372		⁽¹⁾	06/03/2036	Common Stock	24,372	$0	24,372	D

Explanation of Responses:

1. The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

	/s/ Joshua B. Cohen, as Attorney in Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Amylyx Pharmaceuticals (AMLX) report for Daphne Quimi?

Amylyx Pharmaceuticals reported that director Daphne Quimi received a stock option grant for 24,372 shares of Common Stock. The options are part of her compensation and give her the right to buy shares at a fixed price in the future.

What is the exercise price of Daphne Quimi’s new Amylyx (AMLX) stock options?

The granted stock options allow Daphne Quimi to purchase 24,372 Amylyx shares at an exercise price of $14.31 per share. This fixed price means she can later buy shares at that level regardless of future market prices.

When do Daphne Quimi’s Amylyx (AMLX) stock options vest and become exercisable?

The options vest in full on the earlier of June 4, 2027 or the date of the next annual shareholder meeting. Vesting is conditional on Daphne Quimi maintaining continuous service with Amylyx through that vesting date.

When do Daphne Quimi’s newly granted Amylyx (AMLX) stock options expire?

The stock options granted to Daphne Quimi expire on June 3, 2036. After this expiration date, any unexercised portion of the 24,372-share option grant will lapse and can no longer be used to purchase Amylyx stock.

How many Amylyx (AMLX) derivative securities does Daphne Quimi hold after this Form 4 transaction?

Following this transaction, Daphne Quimi holds 24,372 stock options according to the filing. This matches the number of options granted, indicating this grant constitutes her reported derivative position in this particular Form 4.